5Boeck S, Hausmann A, Reibke R, et al. Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer [J]. Anticancer Drugs, 2007, 18 (9) : 1109-1111.
二级参考文献18
1吴一龙,蒋国梁,陆舜,等.中国肺癌临床指南[M].北京:人民卫生出版社,2007:73.
2Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ studies[J].Clin Cancer Res, 2007, 13( 13 ): 3913-3921.
3Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase Ⅲ trial of erlotinib hydrochloride ( OSI-774 ) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer[J].J Clin Oncol, 2005, 23 ( 25 ) : 5892-5899.
4P e rez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with Erlotinib in patients with non-small cell lung cancer[J].J Clin Oncol,2004,22 ( 16 ): 3238-3247.
5Milton DT, Azzoli CG, Heelan RT, et al.A phase I / Ⅱstudy of weekly high-dose erlotinib in previously treated patients with non-smaU cell lung cancer[J]. Cancer, 2006,107 (5): 1034-1041.
6National Cancer Institute( NCI ).Common toxicity criteria ( CTC ) Version 2.0[J]. The Oncologist May, 2007, 12 ( 5 ) : 610-621.
7Perez-Soler R, Saltz L.Cutaneous adverse effects with HER1/EGFR-targeted agents : is there a silver lining[J].J Clin Oncol, 2005,23 ( 22 ) : 5235-5246.
8Bonomi P.Erlelinib: a am therapeutic approach for non.small cell lung cancer[J]. Expert Opin Investig Drugs,2003,12: 1395-1401.
9Zalcman G.EGFR pathway and mechanism of action of tyrosine kinase inhihitors[J]. Rev Pneumol C1in,2007,63: 285-286.
10Natale RB.Bidogically targeted treatment of non-small-cell lung cancer focus on epidermal growth factor receptor[J]. Clin Lung Cancer,2003,5 ( Suppl 1 ) : S11-17.
